Global Congestive Renal Failure (CRF) Market, By Type (CRF With Cardiorenal Syndrome, CRF With Non-Cardiorenal Syndrome, Others), Treatment (Surgery, Medication, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) – Industry Trends and Forecast to 2029.
Congestive Renal Failure (CRF) Market Analysis and Size
The global congestive renal failure (CRF) market is expected to witness significant growth during the forecast period. Factors such as gross domestic product (GDP) and the increasing inflation rate are expected to affect the CRF market's development. Growing prevalence of kidney failure worldwide and evolving markets are the factors responsible for the growth of this market. COVID-19 also had a major impact on the congestive renal failure (CRF) market.
Data Bridge Market Research analyses a growth rate in the global congestive renal failure (CRF) market in the forecast period 2022-2029. The global congestive renal failure (CRF) market is expected to have a healthy CAGR in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Congestive renal failure is the end-stage kidney failure in which kidney fails to sufficiently filter the waste product from the blood. It can occur due to cardiovascular vascular diseases (such as congestive heart failure and hypertension) and other kidney diseases, including family history with renal failure.
Congestive Renal Failure (CRF) Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2014 - 2019) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
By Type (CRF With Cardiorenal Syndrome, CRF With Non-Cardiorenal Syndrome, Others), Treatment (Surgery, Medication, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
GlaxoSmithKline Plc. (U.K.), Sun Pharmaceutical Industries Ltd (India), Novartis AG (Switzerland), Mylan N.V. (U.S.), Lupin (India), Teva Pharmaceutical Industries Ltd. (Israel) |
|
Market Opportunities |
|
Global Congestive Renal Failure (CRF) Market Dynamics
Drivers
- Increasing Incidence of Kidney Diseases
Chronic kidney disease (CKD) serves as a strong and independent risk factor for cardiovascular disease (CVD). For instance, the prevalence of CVD in CKD patients reaches 63%, in U.S. in contrast with only 5.8% in people without CKD, and this margin is directly correlated with the adversity of CKD.
- Government Initiatives
The market is expected to grow rapidly in the mentioned forecast period due to the increasing incidence and prevalence of kidney diseases in the elderly. Key companies taking the initiative in the development of new drugs and therapies for the treatment associated with various pipeline drugs is expected to boost the market growth.
Opportunities
- Rising Incidence of Hypertension and Diabetes
According to the WHO 2019, approximately 1.13 billion people worldwide have hypertension. In the year range 2014–2016, diabetes and hypertension were responsible for nearly 75% of kidney failure. Diabetes is the major cause of advanced kidney disease, followed by hypertension, which is estimated to affect around 1 billion population globally. Hence, this factor is creating much opportunity in the global congestive renal failure market.
- Advanced Clinical Research and Technological Advancement
Advancements in the technology used in the treatment for congestive renal failure are aiding in providing better care and satisfaction along with the outstanding results are boosting the consumption and growth of the congestive renal failure market
Restraints/Challenges
- Lack of skilled professionals
The lack of qualified personnel who are unable to perform the treatment could curb the growth of the global congestive renal failure (CRF) market over a forecast period.
- High Cost
The huge expenditure required for the surgeries or the treatment surely hamper the market growth.
This global congestive renal failure (CRF) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global congestive renal failure (CRF) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Congestive Renal Failure (CRF) Market
Considering the present scenario, COVID-19 has left an unprecedented global public health crisis that has impacted practically every business. Its long-term repercussions are expected to influence industry growth during the forecast period.
In the post-pandemic era, COVID-19 is expected to positively impact the congestive renal failure (CRF) market, attributing to the increasing number of comorbid diseases such as diabetes or end-stage renal disease market (ESRD).
Global Congestive Renal Failure (CRF) Market Scope
The global congestive renal failure (CRF) market is segmented on the basis of type, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- CRF With Cardiorenal Syndrome
- CRF With Non-Cardiorenal Syndrome
- Others
Treatment
- Surgery
- Medication
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-User
- Hospitals
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Others
Congestive Renal Failure (CRF) Market Regional Analysis/Insights
The global congestive renal failure (CRF) market is analysed and market size insights and trends are provided by type, treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global congestive renal failure (CRF) market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America holds the largest market share due to increased smoking & obesity which causes infection in kidney, growing population with kidney dysfunction.
Asia-Pacific is expected to hold the largest market share due to increased prevalence of kidney damage, increasing population with dialysis treatment and increasing initiatives by government & pharmaceutical organizations to spread awareness.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Congestive Renal Failure (CRF) Market Share Analysis
The global congestive renal failure (CRF) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global congestive renal failure (CRF) market.
Key players operating in the global congestive renal failure (CRF) market include:
- GlaxoSmithKline Plc. (U.K.)
- Sun Pharmaceutical Industries Ltd (India)
- Novartis AG (Switzerland)
- Mylan N.V. (U.S.)
- Lupin (India)
- Teva Pharmaceutical Industries Ltd. (Israel)
SKU-
